Recent studies in SARS-CoV2 have strengthened the evidence that anti-IFN autoantibodies have functional consequences in the setting of infection, as antibodies directed against type I IFNs have been measured in patients who suffer severe disease outcomes from COVID19 (76–78). The gene discussed is IFNA1; the disease is infection.